Ayala Pharmaceuticals Inc (ADXS) USD0.001
Sell:$0.03Buy:$0.03
No change
- This stock can be held in a
Stocks and Shares ISA
Fund and Share AccountNo changeNo changeCompany Information
About this company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.
Key people
Key facts
- EPIC-
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS0076244062
- Market cap$1.22m
- Employees20
- Shares in issue42.67m
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.